Navigation Links
What is the suppressing effect of the PPAR-gamma ligands on stomach cancer cells?
Date:2/17/2009

PPAR- gamma is manifested in a variety of tissues and cancer cells and the ligands that activate PPAR- PPAR- are currently being studied as a novel treatment. The PPAR-gamma ligand generally decreases the survival rate of cancer cells via differentiation, apoptotic induction, and changes in genes or proteins associated with entrance into the G1/S phase. There have been some reports suggesting that stomach cancer cells manifest PPAR- gamma and are suppressed by the PPAR- gamma ligand. Recently, another report has shown that troglitazone, the ligand of PPAR- gamma , may prove useful in preventive medicine, and this effect is dependent on PPAR- gamma .

A research article to be published in volume 15 on January 21, 2009 in the World Journal of Gastroenterology addresses this point. A research team led by Professor DH Kim from the Medical Research Institute, Pusan National University Hospital, Korea found that the reaction of the PPAR- gamma agonist pathway on PPAR- gamma , troglitazone, suppresses the proliferation of colon cancer cells, and induces apoptosis, and expression of the growth response-1 gene in early phase. These processes are activated downstream of the suppression one by one via a PPAR- gamma -independent pathway. Moreover, an inductive chemical compound associated with CDDO causes PPAR- gamma -dependent caveolin expression and a PPAR- gamma -independent induction of the apoptosis reaction.

This report shows that ciglitazone and troglitazone suppress the proliferation of stomach cancer cells via the arrest of G1 phase. The arrest of G1 phase was reported in colon cancer cells via activation of PPAR- gamma. Also, each of the stomach cancer cell types which demonstrated p53 mutations were suppressed more strongly by troglitazone than by ciglitazone, and this effect was more evident in the SNU-668 than in the SNU-216 cells. SNU-668 cells demonstrated p53 and ras mutations, and it will be necessary in future studies to clarify the relationship between these results and the underlying mechanisms. This means that the concentrations of troglitazone that are used clinically suppress the growth of stomach cancer cells, and this may be used as a method to target therapy of gastric cancer.


'/>"/>

Contact: Lin Tian
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Escape cancer, but age sooner? The dark side of the tumor suppressing process
2. USC researchers identify novel approach for suppressing prostate cancer development
3. Cancer-Suppressing Gene Tied to Female Fertility
4. Study shows suppressing herpes virus may reduce infectiousness of HIV
5. MU researcher demonstrates non-traditional therapy is effective as pain management
6. Absolutely PR's Maggie Holben Participates In CBSA BioBreakfast Expert Panel "How to Garner Media Attention & Effectively Use Public Relations Tactics"
7. Newly Published Menopause Study: Bioidentical and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
8. Drug Rehab Mountainside Treatment Center is an Effective and Quality Option for Those Seeking Drug Treatment - Located Close to NY MA
9. The Effects of Probiotics on the Aging Digestive Tract to be Presented at Nutracon 2009
10. Potential atherosclerosis drug exhibits no harmful side-effects in liver
11. Union Springs Pharmaceuticals Introduces New, More Effective Respirator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
Breaking Medicine Technology: